It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Protein post-translational modifications (PTMs) are crucial for cancer cells to adapt to hypoxia; however, the functional significance of lysine crotonylation (Kcr) in hypoxia remains unclear. Herein we report a quantitative proteomics analysis of global crotonylome under normoxia and hypoxia, and demonstrate 128 Kcr site alterations across 101 proteins in MDA-MB231 cells. Specifically, we observe a significant decrease in K131cr, K156cr and K220cr of phosphoglycerate kinase 1 (PGK1) upon hypoxia. Enoyl-CoA hydratase 1 (ECHS1) is upregulated and interacts with PGK1, leading to the downregulation of PGK1 Kcr under hypoxia. Abolishment of PGK1 Kcr promotes glycolysis and suppresses mitochondrial pyruvate metabolism by activating pyruvate dehydrogenase kinase 1 (PDHK1). A low PGK1 K131cr level is correlated with malignancy and poor prognosis of breast cancer. Our findings show that PGK1 Kcr is a signal in coordinating glycolysis and the tricarboxylic acid (TCA) cycle and may serve as a diagnostic indicator for breast cancer.
The functional relevance of lysine crotonylation in cancer remains to be further explored. Here, the authors show that hypoxia-induced downregulation of PGK1 lysine crotonylation promotes glycolysis and suppresses mitochondrial pyruvate metabolism, contributing to breast cancer progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Capital Medical University, Beijing Institute of Hepatology, Beijing Youan Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Capital Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
2 Capital Medical University, Beijing Institute of Hepatology, Beijing Youan Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
3 Westlake Laboratory of Life Sciences and Biomedicine, Westlake Four-Dimensional Dynamic Metabolomics (Meta4D) Laboratory, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315)
4 Capital Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
5 Capital Medical University, Beijing Institute of Hepatology, Beijing Youan Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Capital Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Tianjin Medical University Cancer Institute and Hospital, Department of Cancer Cell Biology and National Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)
6 Capital Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Westlake Laboratory of Life Sciences and Biomedicine, Westlake Four-Dimensional Dynamic Metabolomics (Meta4D) Laboratory, Hangzhou, China (GRID:grid.494629.4) (ISNI:0000 0004 8008 9315)